The PPARs: From Orphan Receptors to Drug Discovery
The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTThe PPARs: From Orphan Receptors to Drug Discovery†Timothy M. Willson, Peter J. Brown, Daniel D. Sternbach, and Brad R. HenkeView Author Information Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709 Cite this: J. Med. Chem. 2000, 43, 4, 527–550Publication Date (Web):February 24, 2000Publication History Received8 November 1999Published online24 February 2000Published inissue 1 February 2000https://pubs.acs.org/doi/10.1021/jm990554ghttps://doi.org/10.1021/jm990554greview-articleACS PublicationsCopyright © 2000 American Chemical SocietyRequest reuse permissionsArticle Views6740Altmetric-Citations1452LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Agonists,Ligands,Lipids,Receptors,Rodent models Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pemafibrate is an extremely selective PPARα agonist (subtype selectivity > 5000-fold for PPARγ and > 11,000-fold for PPARδ, respectively) [49, 50].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
In the citing paper
“The PPARα activation by pemafibrate was > 2500 times stronger than fenofibric acid, the active form of fenofibrate.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
Citations
Cites
Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale
DeRisi, J. L., Iyer, V. R., & Brown, P. O. (1997) · Science · doi:10.1126/science.278.5338.680 · Cited by 4,456
Self-citationA Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationActivation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Research works printed but not linked: 124
- Lichtenstein A. H., 1998, Nutr. Rev., 56, S28
- Harris M. I., 1998, Diabetes Care, 21, 524
- Howard B. V., 1995, Int. Congr. Ser.
- Barzilai N., 1999, J. Gerontol., Ser. A, 54, B96
- Lichtenstein A. H., 1999, Nutr. Rev., 57, 14
- Jump D. B., 1999, Annu. Rev. Nutr., 19, 90
- Mangelsdorf D. J., 1995, Cell, 83, 850
- A, 1999, Cell, 97, 163
- Xu H. E., 1999, Mol. Cell, 3, 403
- Hu E., 1996, Science, 274, 2103
- Zhang B., 1996, J. Biol. Chem., 271, 31774
- Adams M., 1997, J. Biol. Chem., 272, 5132
- Camp H. S., 1999, Endocrinology, 140, 397
- Juge-Aubry C. E., 1999, J. Biol. Chem., 274, 10510
- McDonnell D. P., 1993, Bio/Technology, 11, 1261
- Lehmann J. M., 1995, J. Biol. Chem., 270, 12956
- Xu L., 1999, Curr. Opin. Genet. Dev., 9, 147
- Zhu Y., 1996, Gene Expression, 6, 195
- Dowell P., 1997, J. Biol. Chem., 272, 33443
- Zhu Y., 1997, J. Biol. Chem., 272, 25506
- Yuan C.-X., 1998, Proc. Natl. Acad. Sci. U.S.A., 95, 7944
- Treuter E., 1998, Mol. Endocrinol., 12, 881, 10.1210/mend.12.6.0123 · doi:10.1210/mend.12.6.0123 · Paper page
- Krey G., 1997, Mol. Endocrinol., 11, 791, 10.1210/mend.11.6.0007 · DOI · Paper page
- Zhou G., 1998, Mol. Endocrinol., 12, 1604, 10.1210/mend.12.10.0176 · doi:10.1210/mend.12.10.0176 · Paper page
- Berger J., 1996, Endocrinology, 137, 4195
- Young P. W., 1998, J. Pharmacol. Exp. Ther., 284, 759
- Bell A. R., 1998, Biochem. J., 332, 693
- Heuvel J. P. V, 1999, Toxicol. Sci., 47, 8
- Palmer C. N. A., 1998, Mol. Pharmacol., 53, 22
- Gervois P., 1999, Mol. Endocrinol., 13, 1549
- Gaw A., 1994, Handb. Exp. Pharmacol., 109, 348
- Brown P. J., 1997, Synthesis, 778, 782
- Brown P. J., 1999, J. Med. Chem., 42, 3788
- Forman B. M., 1997, Proc. Natl. Acad. Sci. U.S.A., 94, 4317
- Yu K., 1995, J. Biol. Chem., 270, 23983
- Palmer C. N. A., 1994, J. Biol. Chem., 269, 18089
- Lee S. S.-T., 1995, Mol. Cell. Biol., 15, 3022
- Peters J. M., 1997, J. Biol. Chem., 272, 27312
- Gaw A., 1999, Lipoproteins Health Dis., 1145, 1160
- Ross S. D., 1999, Arch. Intern. Med., 159, 1802
- Oliver M. F., 1984, Lancet, 2, 604
- Rutolo G., 1998, J. Am. Coll. Cardiol., 32, 1656
- Libby P., 1999, Mol. Basis Cardiovasc. Dis., 349, 366
- Spencer N. F. L., 1997, Int. Immunol., 9, 1588
- Delerive P., 1999, J. Biol. Chem., 45, 32054
- Vazquez M., 1995, Br. J. Pharmacol., 116, 2075
- Jacobsson A., 1985, J. Biol. Chem., 260, 16254
- Krook A., 1998, Diabetes, 47, 1531
- Ruyter B., 1997, Biochim. Biophys. Acta, 1348, 338
- Zhu Y., 1993, J. Biol. Chem., 268, 26820
- Greene M. E., 1995, Gene Expression, 4, 299
- Chawla A., 1994, Endocrinology, 135, 800, 10.1210/endo.135.2.8033830 · doi:10.1210/endo.135.2.8033830 · Paper page
- Saladin R., 1999, Cell Growth Differ., 10, 48
- Martin G., 1997, J. Biol. Chem., 272, 28217
- Hofmann C., 1994, Endocrinology, 134, 270, 10.1210/endo.134.1.8275942 · DOI · Paper page
- Tai T.-A. C., 1996, J. Biol. Chem., 271, 29914
- Kelly L. J., 1998, Endocrinology, 139, 4927
- Hulin B., 1996, Curr. Pharm. Des., 2, 102
- Kletzien R. F., 1992, Mol. Pharmacol., 41, 398
- Ibrahimi A., 1994, Mol. Pharmacol., 46, 1076
- Harris P. K. W., 1994, Mol. Pharmacol., 45, 445
- Willson T. M., 1996, J. Med. Chem., 39, 668
- Ide T., 1998, Diabetes Front, 9, 346
- Shinkai H., 1998, J. Med. Chem., 41, 1933
- Reginato M. J., 1998, J. Biol. Chem., 273, 32684
- Reddy K. A., 1999, J. Med. Chem., 42, 3278
- Sohda T., 1984, Chem. Pharm. Bull., 32, 4465
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2126
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2130
- Henke B. R., 1998, Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem
- Collins J. L., 1998, Structure−activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem
- Cobb J. E., 1998, N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists. 3. Structure−activity relationship and optimization of the N-aryl substituent. J. Med. Chem., 41, 5069
- Lehmann J. M., 1997, J. Biol. Chem., 272, 3410
- Verrando P., 1981, Biochim. Biophys. Acta, 663, 265
- Negishi M., 1995, J. Lipid Mediators Cell Signalling, 12, 448
- Narumiya S., 1991, Dev. Oncol., 67, 448
- Ikeda H., 1990, Arzneim.-Forsch., 40, 162
- Horikoshi H., 1994, Annu. Rep. Sankyo Res. Lab., 46, 57
- Prigeon R. L., 1998, J. Clin. Endocrinol. Metab., 83, 823
- Fonseca V. A., 1998, J. Clin. Endocrinol. Metab., 83, 3176
- Spencer C. M., 1997, Drugs, 54, 101
- Kumar S., 1996, Diabetologia, 39, 709
- Gimble J. M., 1996, Mol. Pharmacol., 50, 1094
- Jones S. A., 2000, Mol. Endocrinol., 14, 39, 10.1210/mend.14.1.0409 · doi:10.1210/mend.14.1.0409 · Paper page
- Blumberg B., 1998, Genes Dev., 12, 3205
- Ramachandran V., 1999, Drug Metab. Dispos., 27, 1199
- Yamazaki H., 1999, Drug Metab. Dispos., 27, 1266
- Pumford N. R., 1997, Annu. Rev. Pharmacol. Toxicol., 37, 117
- Miller V. A., 1997, J. Clin. Oncol., 15, 795
- Rizvi N. A., 1999, Clin. Cancer Res., 5, 1664
- Vidal-Puig A. J., 1997, J. Clin. Invest., 99, 2422
- Park K. S., 1997, Diabetes, 46, 1234
- Wu Z., 1998, J. Clin. Invest., 101, 32
- Sreenan S., 1999, Am. J. Physiol., 276, E1129
- Miles P. D. G., 1997, Diabetes, 46, 1683
- Yen C.-J., 1997, Biochem. Biophys. Res. Commun., 241, 274
- Deeb S. S., 1998, Nat. Genet., 20, 287
- Valve R., 1999, J. Clin. Endocrinol. Metab., 84, 3712
- Mori Y., 1998, Biochem. Biophys. Res. Commun., 251, 198
- Ek J., 1999, Diabetologia, 42, 895
- Hamann A., 1999, Eur. J. Endocrinol., 141, 92
- Girard J, 1997, Diabetes Metab., 23, 24
- McKeigue P., 1997, Handb. Hypertens., 17, 934
- Dubey R. K., 1993, Am. J. Physiol., 265, R732
- Zhang H. Y., 1994, Hypertension, 24, 110
- Morikang E., 1997, Am. J. Hypertens., 10, 446
- Law R. E., 1996, J. Clin. Invest., 98, 1905
- Kotchen T. A., 1996, Am. J. Physiol., 270, R666
- Zhang F., 1994, Hypertension, 24, 175
- Su C. G., 1999, J. Clin. Invest., 104, 389
- Ehrmann D. A., 1997, J. Clin. Endocrinol. Metab., 82, 2116
- Minamikawa J., 1998, J. Clin. Endocrinol. Metab., 83, 1820
- Suh N., 1999, Cancer Res., 59, 5673
- Lefebvre A.-M., 1998, Nat. Med., 4, 1057
- Schmidt A., 1992, Mol. Endocrinol., 6, 1641
- Amri E.-Z., 1995, J. Biol. Chem., 270, 2371
- Brooks C. D. W., 1996, J. Med. Chem., 39, 2654
- Brun R. P., 1996, Genes Dev., 10, 984
- Lim H., 1999, Genes Dev., 13, 1574
- He T.-C., 1999, Cell, 99, 345
- Cobb J., 1998, Annu. Rep. Med. Chem., 33, 222
- Sliskovic D. R., 1999, Annu. Rep. Med. Chem., 34, 110
- Belch J. J. F., 1998, Proc. Nutr. Soc., 57, 569
- Woutersen R. A., 1999, Mutat. Res., 443, 127
Cited by
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
“However, it is probable that PPARγ is the biological target of the anti-diabetic actions of TZDs: there is a strong correlation between PPARγ binding in vitro and glucose lowering in vivo”
BackgroundThe mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Nuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Pawlak, M., Lefebvre, P., & Staels, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.039 · Cited by 1,578
“Moreover, despite numerous reports of beneficial effects of fibrates in mice, species-specific differences may exist in the response to PPARa agonism [32].”
BackgroundBouhlel, M. A., Derudas, B., Rigamonti, E., Dièvart, R., Brozek, J., Haulon, S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.06.010 · Cited by 1,325
Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001) · Nature Medicine · doi:10.1038/83348 · Cited by 1,170
“We treated these cells with either the PPAR-α ligand Wy14643 or the PPAR-γ ligand rosiglitazone at concentrations of 2–3 times their EC 50 values (Wy14643 EC 50 for human PPAR-αe25 μM and rosiglitazone EC 50 for human PPAR-γe43 nM”
Benson, S. C., Pershadsingh, H. A., Ho, C. I., Chittiboyina, A., Desai, P., Pravenec, M., Qi, N., Wang, J., Avery, M. A., & Kurtz, T. W. (2004) · Hypertension · doi:10.1161/01.hyp.0000123072.34629.57 · Cited by 1,073
Fu, J., Gaetani, S., Oveisi, F., Lo Verme, J., Serrano, A., Rodríguez de Fonseca, F., Rosengarth, A., Luecke, H., Di Giacomo, B., Tarzia, G., et al. (2003) · Nature · doi:10.1038/nature01921 · Cited by 1,064
Grygiel-Górniak, B. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-17 · Cited by 1,079
“The effect of bezafibrate, another compound from this group, is wider because it activates all 3 PPAR subtypes (α, γ and δ) at comparable doses to other fibrates [1,5].”
BackgroundInfluentialOliver, W. R., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091021198 · Cited by 1,046
Self-citationInternational Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,000
Peroxisome Proliferator-Activated Receptor Alpha Target Genes
Rakhshandehroo, M., Knoch, B., Müller, M., & Kersten, S. (2010) · PPAR Research · doi:10.1155/2010/612089 · Cited by 1,020
“[10] T.”
BackgroundTyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017
“[10,11] PPAR-α ligands can be both synthetic or endogenous FAs and FA-derived compounds are natural ligands for PPAR-α.”
BackgroundInfluentialNew drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,008
“PPARγ is the predominant molecular target for insulin-sensitizing thiazolidinedione (TZD) drug”
BackgroundReddy, J. K., & Hashimoto, T. (2001) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.21.1.193 · Cited by 959
Emerging roles of PPARS in inflammation and immunity
Daynes, R. A., & Jones, D. C. (2002) · Nature Reviews Immunology · doi:10.1038/nri912 · Cited by 919
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
New developments in adipogenesis
Lefterova, M. I., & Lazar, M. A. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2008.11.005 · Cited by 863
Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006353 · Cited by 882
“We genetically modified HeLa cells to stably express a luciferase reporter gene together with the ligand-binding domain of human PPAR- (Willson et al., 2000) and used these cells to determine whether PEA engages this receptor.”
Li, A. C., Brown, K. K., Silvestre, M. J., Willson, T. M., Palinski, W., & Glass, C. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10370 · Cited by 833
Self-citationTanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832
Cyclooxygenase‐independent actions of cyclooxygenase inhibitors
Tegeder, I., Pfeilschifter, J., & Geisslinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.01-0390rev · Cited by 747
“Three distinct PPAR isoforms—PPARa, d, and g—have been isolated and characterized (147).”
BackgroundDocosahexaenoic Acid, a Ligand for the Retinoid X Receptor in Mouse Brain
Urquiza, A. M. D., Liu, S., Sjöberg, M., Zetterström, R. H., Griffiths, W., Sjövall, J., & Perlmann, T. (2000) · Science · doi:10.1126/science.290.5499.2140 · Cited by 742
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses
Christofides, A., Konstantinidou, E., Jani, C., & Boussiotis, V. A. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154338 · Cited by 720
Janani, C., & Ranjitha Kumari, B. D. (2015) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2014.09.015 · Cited by 735
Integrated physiology and systems biology of PPARα
Kersten, S. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.02.002 · Cited by 670
“Fibrates not only bind to PPARa more avidly compared with fatty acids [48,161], but likely also cause a slightly different conformational change in the PPARa protein as dictated by the SPPARM concept [119], together leading to slightly altered and generally more robust induction of target genes by fibrates.”
BackgroundRecent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
MUSSO, G., GAMBINO, R., & CASSADER, M. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.08.001 · Cited by 681
Bays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
“Similar beneficial effects on glucose homeostasis can be expected from nonthiazolidinedione PPAR agonists (283, 284).”
BackgroundInfluentialPPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance
Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C., David, R. M., DeLuca, J. G., Lai, D. Y., McKee, R. H., Peters, J. M., et al. (2003) · Critical Reviews in Toxicology · doi:10.1080/713608372 · Cited by 611
“Long-chain unsaturated fatty acids such as linoleic acid, polyunsaturated fatty acids (PUFAs) including arachidonic, eicosapentaenoic, and linolenic acids, and the branched-chain fatty acid phytanic acid bind to PPARα with reasonable affinity (in the µM range) (Willson et al., 2000).”
BackgroundInfluentialPeroxisome Proliferator–Activated Receptor γ and Metabolic Disease
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.341 · Cited by 582
Self-citationGampe, R. T., Montana, V. G., Lambert, M. H., Miller, A. B., Bledsoe, R. K., Milburn, M. V., Kliewer, S. A., Willson, T. M., & Xu, H. E. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80448-7 · Cited by 574
Self-citationLi, A. C., Binder, C. J., Gutierrez, A., Brown, K. K., Plotkin, C. R., Pattison, J. W., Valledor, A. F., Davis, R. A., Willson, T. M., Witztum, J. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18730 · Cited by 573
Self-citationSavage, D. B., Sewter, C. P., Klenk, E. S., Segal, D. G., Vidal-Puig, A., Considine, R. V., & O’Rahilly, S. (2001) · Diabetes · doi:10.2337/diabetes.50.10.2199 · Cited by 572
Combs, T. P., Wagner, J. A., Berger, J., Doebber, T., Wang, W.-J., Zhang, B. B., Tanen, M., Berg, A. H., O’Rahilly, S., Savage, D. B., et al. (2002) · Endocrinology · doi:10.1210/endo.143.3.8662 · Cited by 565
“occur more gradually, over the course of 6–12 wk (7, 37).”
BackgroundLeesnitzer, L. M., Parks, D. J., Bledsoe, R. K., Cobb, J. E., Collins, J. L., Consler, T. G., Davis, R. G., Hull-Ryde, E. A., Lenhard, J. M., Patel, L., et al. (2002) · Biochemistry · doi:10.1021/bi0159581 · Cited by 566
Self-citationXu, H. E., Lambert, M. H., Montana, V. G., Plunket, K. D., Moore, L. B., Collins, J. L., Oplinger, J. A., Kliewer, S. A., Gampe, R. T., McKee, D. D., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241410198 · Cited by 538
Self-citationAsymmetric Hydrogenation of Olefins Using Chiral Crabtree-type Catalysts: Scope and Limitations
Verendel, J. J., Pàmies, O., Diéguez, M., & Andersson, P. G. (2014) · Chemical Reviews · doi:10.1021/cr400037u · Cited by 505
Pineda Torra, I., Claudel, T., Duval, C., Kosykh, V., Fruchart, J.-C., & Staels, B. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0120 · Cited by 487
“Fatty acid derivatives are natural ligands for PPAR (26).”
BackgroundMuscle-specific Pparg deletion causes insulin resistance
Hevener, A. L., He, W., Barak, Y., Le, J., Bandyopadhyay, G., Olson, P., Wilkes, J., Evans, R. M., & Olefsky, J. (2003) · Nature Medicine · doi:10.1038/nm956 · Cited by 492
Peroxisome proliferator-activated receptors and hepatic stellate cell activation
Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473
Self-citationCan we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
Pathological aspects of lipid peroxidation
Negre-Salvayre, A., Auge, N., Ayala, V., Basaga, H., Boada, J., Brenke, R., Chapple, S., Cohen, G., Feher, J., Grune, T., et al. (2010) · Free Radical Research · doi:10.3109/10715762.2010.498478 · Cited by 449
Desreumaux, P., Dubuquoy, L., Nutten, S., Peuchmaur, M., Englaro, W., Schoonjans, K., Derijard, B., Desvergne, B., Wahli, W., Chambon, P., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.827 · Cited by 457
“scription factor (ATF)2(1-109), 50 mM ATP, and 3–10 mCi of [g-32P]ATP as substrates in 20 ml of kinase buffer (20).”
BackgroundLipid Accumulation and Chronic Kidney Disease
Gai, Z., Wang, T., Visentin, M., Kullak-Ublick, G., Fu, X., & Wang, Z. (2019) · Nutrients · doi:10.3390/nu11040722 · Cited by 421
“Because endogenous ligands such as long chain polyunsaturated fatty acids and eicosanoid derivatives can activate PPARγ, it is conceivable that PPARγ agonists can be used for reducing lipid systemic levels and renal lipid accumulation in obese patients with CKD [99,100].”
BackgroundAntineoplastic effects of peroxisome proliferatoractivated receptor γ agonists
Grommes, C., Landreth, G. E., & Heneka, M. T. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01509-8 · Cited by 440
Lipid-Based Delivery Systems and Intestinal Lymphatic Drug Transport: A Mechanistic Update
Trevaskis, N. L., Charman, W. N., & Porter, C. J. H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.09.007 · Cited by 442
“peroxisome proliferator activated receptors (PPAR) [118,121]) which influence FABP transcription and expression in response to lipid ingestion further influence the transcriptional expression of a number of proteins implicated in intestinal lipid absorption [122].”
BackgroundContribution of inflammatory processes to Alzheimer's disease: molecular mechanisms
Sastre, M., Klockgether, T., & Heneka, M. T. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.014 · Cited by 426
mTOR , metabolism, and the regulation of T‐cell differentiation and function
Waickman, A. T., & Powell, J. D. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01152.x · Cited by 420
“It has been shown that polyunsaturated acids (such as linoleic acid and aracidonic acid), eicosanoids, and many synthetic ligands (such as TZDs and tyrosine agonists) can bind to PPARc with high affinity and induce nuclear translocation (128, 143, 144).”
BackgroundBarbier, O., Torra, I. P., Duguay, Y., Blanquart, C., Fruchart, J.-C., Glineur, C., & Staels, B. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000015598.86369.04 · Cited by 416
Gilde, A. J., van der Lee, K. A. J. M., Willemsen, P. H. M., Chinetti, G., van der Leij, F. R., van der Vusse, G. J., Staels, B., & van Bilsen, M. (2003) · Circulation Research · doi:10.1161/01.res.0000060700.55247.7c · Cited by 399
Gupta, R. A., Tan, J., Krause, W. F., Geraci, M. W., Willson, T. M., Dey, S. K., & DuBois, R. N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.24.13275 · Cited by 401
Self-citationThe role and regulation of the peroxisome proliferator activated receptor alpha in human liver
Kersten, S., & Stienstra, R. (2017) · Biochimie · doi:10.1016/j.biochi.2016.12.019 · Cited by 394
Diabetes mellitus: complications and therapeutics.
Tripathi, B. K., & Srivastava, A. K. (2006) · PubMed · Cited by 493
Thematic review series: Skin Lipids. Sebaceous gland lipids: friend or foe?
Smith, K. R., & Thiboutot, D. M. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r700015-jlr200 · Cited by 388
“PPARs are orphan nuclear receptors that exert their action by forming heterodimers with retinoid X receptors and binding to specific response elements on DNA consisting of direct repeats of AGGTCA spaced by one nucleotide (DR-1 sites) (56).”
Vallée, A., & Lecarpentier, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00745 · Cited by 374
Nishiyama, T., Mae, T., Kishida, H., Tsukagawa, M., Mimaki, Y., Kuroda, M., Sashida, Y., Takahashi, K., Kawada, T., Nakagawa, K., et al. (2005) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf0483873 · Cited by 366
De Novo Design of Bioactive Small Molecules by Artificial Intelligence
Merk, D., Friedrich, L., Grisoni, F., & Schneider, G. (2018) · Molecular Informatics · doi:10.1002/minf.201700153 · Cited by 373
ZOETE, V, GROSDIDIER, A., & MICHIELIN, O. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.01.007 · Cited by 358
Microglia Function in Alzheimer’s Disease
Solito, E., & Sastre, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00014 · Cited by 349
“A potential downstream target of some NSAIDs such as ibuprofen, indomethacin, and naproxen is the peroxisome proliferatoractivated receptor-γ (PPAR-γ; Lehmann et al., 1997; Willson et al., 2000).”
BackgroundSastre, M., Dewachter, I., Landreth, G. E., Willson, T. M., Klockgether, T., van Leuven, F., & Heneka, M. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-30-09796.2003 · Cited by 357
“In N2a cells, a nonthiazolidinedione PPAR agonist ( Willson et al., 2000 ), GW7845, caused the same effects as pioglitazone (data not shown).”
BackgroundInfluentialSelf-citationWAYMAN, N. S., HATTORI, Y., MCDONALD, M. C., MOTA‐FILIPE, H., CUZZOCREA, S., PISANO, B., CHATTERJEE, P. K., & THIEMERMANN, C. (2002) · The FASEB Journal · doi:10.1096/fj.01-0793com · Cited by 361
“The maximal reductions in infarct size afforded by these TZDs (rosiglitazone: 45%; ciglitazone: 45% and pioglitazone: 25%) appear to correlate positively with their potency as PPAR- agonists in vitro (8).”
BackgroundPPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis
Li, A. C., & Glass, C. K. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400010-jlr200 · Cited by 357
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs
Kotarsky, K., Nilsson, N. E., Flodgren, E., Owman, C., & Olde, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)03064-4 · Cited by 352
Cyclooxygenase-2 and prostaglandins in articular tissues
Martel-Pelletier, J., Pelletier, J.-P., & Fahmi, H. (2003) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(03)00134-3 · Cited by 333
Peroxisome Proliferator–Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown, J. D., & Plutzky, J. (2007) · Circulation · doi:10.1161/circulationaha.104.475673 · Cited by 340
Zollner, G., Marschall, H.-U., Wagner, M., & Trauner, M. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060010s · Cited by 335
Way, J. M., Harrington, W. W., Brown, K. K., Gottschalk, W. K., Sundseth, S. S., Mansfield, T. A., Ramachandran, R. K., Willson, T. M., & Kliewer, S. A. (2001) · Endocrinology · doi:10.1210/endo.142.3.8037 · Cited by 338
“PPARg activation either stimulates (1) or represses (2) key metabolic pathways in adipose, muscle, and liver and promotes a flux of FFA from muscle and liver to adipose.”
BackgroundSelf-citationWang, D., Wang, H., Shi, Q., Katkuri, S., Walhi, W., Desvergne, B., Das, S. K., Dey, S. K., & DuBois, R. N. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.011 · Cited by 340
“nuclear hormone receptor superfamily (Willson et al., 2000).”
Fatty acids, eicosanoids and PPAR gamma
Marion-Letellier, R., Savoye, G., & Ghosh, S. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.11.004 · Cited by 332
“Peroxisome proliferator-activated receptors (PPAR) are nuclear receptors belonging to the steroid receptor superfamily that regulate gene transcription of different pathways, including metabolism and inflammation (Willson et al., 2000).”
BackgroundYoon, M. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.02.004 · Cited by 336
Cronet, P., Petersen, J. F. W., Folmer, R., Blomberg, N., Sjöblom, K., Karlsson, U., Lindstedt, E.-L., & Bamberg, K. (2001) · Structure · doi:10.1016/s0969-2126(01)00634-7 · Cited by 325
Guzmán, M., Lo Verme, J., Fu, J., Oveisi, F., Blázquez, C., & Piomelli, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404087200 · Cited by 328
Lengqvist, J., Mata de Urquiza, A., Bergman, A.-C., Willson, T. M., Sjövall, J., Perlmann, T., & Griffiths, W. J. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400003-mcp200 · Cited by 323
“1 were treated with RXR-specific ligand LG268 (1, 10, 100, and 1000 nM; f), DHA (1, 2, 4, 8, 10, 16, and 32 M; ), PPAR -specific ligand GW7647 ( ), PPAR / -specific ligand GW0742 ( ), or PPAR -specific ligand GW7845 (● ) (0.1, 1, and 10 M for PPAR ligands).”
InfluentialSelf-citationBerger, J. P., Petro, A. E., Macnaul, K. L., Kelly, L. J., Zhang, B. B., Richards, K., Elbrecht, A., Johnson, B. A., Zhou, G., Doebber, T. W., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0217 · Cited by 321
“been shown to correlate with their potency as PPAR agonists in vitro (7, 9, 10).”
BackgroundComparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human
Rakhshandehroo, M., Hooiveld, G., Müller, M., & Kersten, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006796 · Cited by 305
“A 5-fold lower concentration of Wy14643 was used in mouse primary hepatocytes to take into account the higher affinity of Wy14643 for mouse PPARa compared to human PPARa [52].”
BackgroundLee, G., Elwood, F., McNally, J., Weiszmann, J., Lindstrom, M., Amaral, K., Nakamura, M., Miao, S., Cao, P., Learned, R. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200743200 · Cited by 319
Sznaidman, M. L., Haffner, C. D., Maloney, P. R., Fivush, A., Chao, E., Goreham, D., Sierra, M. L., LeGrumelec, C., Xu, H. E., Montana, V. G., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00207-5 · Cited by 312
Self-citationBurgess, H. A., Daugherty, L. E., Thatcher, T. H., Lakatos, H. F., Ray, D. M., Redonnet, M., Phipps, R. P., & Sime, P. J. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00383.2004 · Cited by 317
“This complex recognizes PPAR response elements (PPRE) in promoters on target genes resulting in the regulation of gene transcription (3, 5, 36).”
BackgroundGhonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology · doi:10.1002/hep.27744 · Cited by 317
“*Modified from Wilson et al.(16) Data are for the active metabolite.”
BackgroundInfluentialRapid Broad-Spectrum Analgesia through Activation of Peroxisome Proliferator-Activated Receptor-α
LoVerme, J., Russo, R., La Rana, G., Fu, J., Farthing, J., Mattace-Raso, G., Meli, R., Hohmann, A., Calignano, A., & Piomelli, D. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111385 · Cited by 316
“1); OEA, oleoylethanolamide; FAE, fatty-acid ethanolamide; CB2, cannabinoid receptor type II; WDR, wide dynamic range; PKA, protein kinase A; GW7647, 2-(4-(2-(1-cyclohexanebutyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Wy-14643, 4-chloro-6-(2,3-xyli…”
MethodInfluentialBlanquart, C., Barbier, O., Fruchart, J. C., Staels, B., & Glineur, C. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00214-0 · Cited by 312
Thiadiazole—a Promising Structure in Medicinal Chemistry
Li, Y., Geng, J., Liu, Y., Yu, S., & Zhao, G. (2013) · ChemMedChem · doi:10.1002/cmdc.201200355 · Cited by 303
Kim, Y., Suh, N., Sporn, M., & Reed, J. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202458200 · Cited by 309
Primary biliary cholangitis: pathogenesis and therapeutic opportunities
Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0226-7 · Cited by 308
Michel, M. C., Foster, C., Brunner, H. R., & Liu, L. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007278 · Cited by 301
“The most frequently used approach in this regard is the use of PPAR-g antagonists such as GW9662.”
BackgroundMethodInfluentialTenenbaum, A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1154 · Cited by 311
“Bezafibrate, compared with other fibrates, has a unique characteristic profile of action since it activates all 3 PPAR subtypes ( , , and ) at comparable doses.(42,43) Therefore, bezafibrate operates as a pan-agonist for all 3 PPAR isoforms.”
BackgroundYoshikawa, T., Ide, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Matsuzaka, T., Yatoh, S., Kitamine, T., Okazaki, H., Tamura, Y., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0190 · Cited by 297
Regulation of Macrophage Functions by PPAR-α, PPAR-γ, and LXRs in Mice and Men
Rigamonti, E., Chinetti-Gbaguidi, G., & Staels, B. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.158998 · Cited by 293
Chapman, M. J., Le Goff, W., Guerin, M., & Kontush, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp399 · Cited by 298
“Fibrates are a chemically heterogeneous class of agents, among which the most widely clinically used, fenofibrate, is primarily a PPARa-agonist of moderate affinity.(84) Fibrates bind to PPARa by mimicking the structure of free fatty acids(85) and may increase HDL-C by up to 20% as a function of baseline lipid phenoty…”
BackgroundFeinstein, D. L., Galea, E., Gavrilyuk, V., Brosnan, C. F., Whitacre, C. C., Dumitrescu‐Ozimek, L., Landreth, G. E., Pershadsingh, H. A., Weinberg, G., & Heneka, M. T. (2002) · Annals of Neurology · doi:10.1002/ana.10206 · Cited by 294
“E-mail: dlfeins@uic.edu 694 © 2002 Wiley-Liss, Inc. such as troglitazone, pioglitazone (PIO), and rosiglitazone,15 and tyrosine-based agonists such as GW347845.”
BackgroundInfluentialPeroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
Guan, Y., & Breyer, M. D. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00766.x · Cited by 295
Metabolic and Additional Vascular Effects of Thiazolidinediones
Martens, F. M. A. C., Visseren, F. L. J., Lemay, J., de Koning, E. J. P., & Rabelink, T. J. (2002) · Drugs · doi:10.2165/00003495-200262100-00004 · Cited by 291
“The tissue distribution of these subtypes varies considerably.[10,12] Whereas PPAR-δ is ubiquitously distributed, its function remains to be elucidated.”
BackgroundWallace, K., Burt, A. D., & Wright, M. C. (2008) · Biochemical Journal · doi:10.1042/bj20071570 · Cited by 262
Kohno, H., Suzuki, R., Yasui, Y., Hosokawa, M., Miyashita, K., & Tanaka, T. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03236.x · Cited by 284
HUANG, T., PENG, G., KOTA, B., LI, G., YAMAHARA, J., ROUFOGALIS, B., & LI, Y. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.12.009 · Cited by 272
“Activation of PPAR-g to improve the sensitivity of insulin receptors is the predominant mechanism for the anti-diabetic efficacy of PPAR-g agonists (Willson et al., 2000).”
BackgroundFu, J., Oveisi, F., Gaetani, S., Lin, E., & Piomelli, D. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.02.013 · Cited by 276
Gupta, R. A., Wang, D., Katkuri, S., Wang, H., Dey, S. K., & DuBois, R. N. (2004) · Nature Medicine · doi:10.1038/nm993 · Cited by 275
A Unique PPARγ Ligand with Potent Insulin-Sensitizing yet Weak Adipogenic Activity
Rocchi, S., Picard, F., Vamecq, J., Gelman, L., Potier, N., Zeyer, D., Dubuquoy, L., Bac, P., Champy, M.-F., Plunket, K. D., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00353-7 · Cited by 272
Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues
LeBrasseur, N. K., Kelly, M., Tsao, T.-S., Farmer, S. R., Saha, A. K., Ruderman, N. B., & Tomas, E. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00453.2005 · Cited by 276
“(45) have determined the EC50s of troglitazone and PIO to be in the range of 0.”
BackgroundReceptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?
Feinstein, D. L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., & Russo, C. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.033 · Cited by 275
Metadata
- Authors
- Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R.
- Affiliations
- Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-02-01
- Volume
- 43
- Issue
- 4
- Pages
- 527-550
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1977666051
- Cited by
- 1,816
- References
- 216
- Citations by year
- 2026: 18 · 2025: 28 · 2024: 27 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 38 · 2019: 44 · 2018: 46 · 2017: 44 · 2016: 37 · 2015: 60 · 2014: 62 · 2013: 52 · 2012: 92
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- peroxisome proliferator-activated receptors, orphan receptors, drug discovery, receptor agonists, ligands, lipid signaling, nuclear receptors
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Hyperlipidemias, Hypertension, Inflammation, Ligands, Models, Molecular, Neoplasms, Nuclear Proteins, Obesity, Transcription Factors, Drug Design, Receptors, Cytoplasmic and Nuclear
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.